IGM Biosciences, Inc. is a US-based pharmaceutical company specializing in developing IgM antibody therapeutics for cancer, infectious diseases, and autoimmune conditions. Their innovative IgM antibody technology platform is used to create T cell engagers, receptor cross-linking agonists, and targeted cytokines. Key product candidates include Aplitabart targeting DR5 proteins for colorectal cancer, Imvotamab for severe SLE and RA, and IGM-2644 for autoimmune diseases. With a high ESG risk rating score of 39.0, IGM Biosciences Inc. is at a high-risk level.